NeuroScientific (ASX:NSB) share price soars 23%; Here’s why

June 15, 2022 01:13 PM AEST | By Aditi Sarkar

NeuroScientific (ASX:NSB) share price soars 23%; Here’s why — Image source: © MinervaStudio | Megapixl.com

What are the key highlights of the study?

The study included an evaluation of EMTINB™ across four dose groups (5mg/kg, 10mg/kg, 20mg/kg, and 40mg/kg), with the drug being administered daily for 30 days following the onset of initial symptoms in the mice.

Following are the clinical outcomes from the study (comparison with untreated controls)

Commenting on the results, NeuroScientific’s Managing Director and CEO Matt Liddelow said, “The preliminary results from this study conducted in the gold standard animal model for MS are highly encouraging for the development of EmtinB™ as a treatment for MS, in particular the relapse-remitting type of MS in which inflammation is a key driver of symptoms. In comparison to currently marketed MS therapeutics, EmtinB™ has the potential to be a disease-modifying treatment option for MS patients with a much more tolerable side-effect profile.”

The road ahead

NSB will advance a larger study of EMTINB™ based on these positive preliminary results. The company expects full results in mid-2H 2022.

The company has a market cap of AU$25.10 million.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.